COVID-19 is an emerging, rapidly evolving siituation.
What people with cancer should know: https://www.cancer.gov/coronavirus
Guidance for cancer researchers: https://www.cancer.gov/coronavirus-researchers
Get the latest public health information from CDC: https://www.coronavirus.gov
Get the latest research information from NIH: https://www.nih.gov/coronavirus
The Clinical Proteomic Tumor Analysis Consortium (CPTAC) is pleased to announce its Virtual Scientific Symposium 2020, September 22nd, 2020. This year’s symposium will feature talks by leaders in the field of proteogenomics and will focus on CPTAC’s tumor characterization and translational studies for pediatric brain cancer, acute myeloid leukemia, and glycoproteomics – just to name a few!
Glioblastoma (GBM) is an aggressive brain tumor with poor prognosis despite advancements in treatment and diagnosis. Tumor recurrence, developing in most patients (>90%), poses a major challenge due to tumor heterogeneity and limited understanding of post-treatment evolution. Previous studies have tracked GBM evolution over time but failed to fully explain how resistance to therapy arises.
The Clinical Proteomic Tumor Analysis Consortium (CPTAC) recently held its Scientific Investigator Meeting in Portland, Oregon at the Oregon Health & Science University campus. The meeting featured key scientific and programmatic updates spanning multiple cancer types presented by consortium research investigators. The event also included a poster showcase, and at the end of the event three meritorious posters were selected by Dr. Karin Rodland (Oregon Health & Science University), Dr. Bing Zhang (Baylor College of Medicine), and Dr.
The following is the third entry in a new Q&A series highlighting selected Clinical Proteomic Tumor Analysis Consortium (CPTAC) researchers and their work. Join us as we discuss multiple facets of proteomics research with Nicole Tignor, PhD, Assistant Professor at the Icahn School of Medicine at Mount Sinai. Transcript is edited for clarity.
Small cell lung cancer (SCLC) is an aggressive form of lung malignancy with historically poor prognoses and limited options for targeted treatment. The low availability of suitable biospecimens has also hampered large molecular characterization efforts.
The tumor microenvironment (TME) is a complex network which plays a crucial role in cancer progression and treatment responses. In a recently published Pan Cancer analysis, the Clinical Proteomic Tumor Analysis Consortium (CPTAC) has delved into the TME heterogeneity, exploring cell type composition, immune subtypes, and their associations with various clinical and molecular features. The study leverages proteogenomic data from samples of 1,056 treatment-naive patients with 10 different cancer types.
Acute Myeloid Leukemia (AML) is a hematologic malignancy characterized by the rapid proliferation of abnormal myeloid cells in the bone marrow and blood. AML is known for its heterogeneity, presenting challenges in treatment and predicting patient outcomes.
The following is the second entry in a new Q&A series highlighting selected Clinical Proteomic Tumor Analysis Consortium (CPTAC) researchers and their work. Join us as we discuss multiple facets of proteomics research with Jeffrey Whitaker, PhD, Director of Proteomics within the Paulovich Lab at the Fred Hutchinson Cancer Center. Transcript is edited for clarity.
A new collaboration between the Morehouse School of Medicine (MSM) and the 
Clinical Proteomic Tumor Analysis Consortium (CPTAC) aims to enhance diversity of cancer patients included in proteogenomic studies.
The following is the first entry in a new Q&A series highlighting selected Clinical Proteomic Tumor Analysis Consortium (CPTAC) researchers and their work. Join us as we discuss molecular and computational techniques in biology with Natalie Clark, PhD from the Proteomics Platform at the Broad Institute. Transcript is edited for clarity.
